Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for...